Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
Disclosed is a conjugate for gene transfer, which is capable of being used for treatment of incurable diseases, comprising an oligonucleotide intended to be transferred into target cells and a hydrophilic polymer, wherein an end of the oligonucleotide is covalently conjugated to the hydrophilic polymer. Also, the present invention discloses polyelectrolyte complex micelles formed from such a conjugate and a cationic polymer or cationic peptide. Such polyelectrolyte complex micelles can effectively transfer oligonucleotides as therapeutic agents into target cells, making it possible to obtain desired activities of the delivered oligonucleotides in target cells even when the micelles are clinically applied at a relatively low concentration. Therefore, the conjugate and the polyelectrolyte complex micelle are very useful in basic life science research and the medical field.
1. A conjugate for gene transfer, consisting of an oligonucleotide intended to be transferred into a target cell and a hydrophilic polymer, wherein an end of the oligonucleotide is covalently linked to the hydrophilic polymer via an acetal bond.
2. The conjugate as set forth in claim 1 , wherein the hydrophilic polymer is selected from non-ionic polymers having a molecular weight of over 500 daltons.
3. The conjugate as set forth in claim 1 , wherein the oligonucleotide has a molecular weight ranging from 1,000 to 50,000 daltons.
4. The conjugate as set forth in claim 1 , wherein the hydrophilic polymer is one or more selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone and polyoxazoline.
5. The conjugate as set forth in claim 1 , wherein monomers of the oligonucleotide are linearly linked via a phosphodiester bond.
6. The conjugate as set forth in claim 1 , wherein the oligonucleotide is an antisense oligonucleotide.
7. The conjugate as set forth in claim 6 , wherein the antisense oligonucleotide comprises a nucleotide sequence complementary to a portion or entire nucleotide sequence of c-myc gene.
8. The conjugate as set forth in claim 1 , wherein the conjugate is synthesized by the steps comprising activating an end of an oligonucleotide, and covalently linking a biodegradable hydrophilic polymer to the end of the oligonucleotide.
9. The conjugate as set forth in claim 8 , wherein a chemical compound activating a functional group at the end of the oligonucleotide is selected from 1-ethyl-3,3-dimethylaminopropyl carbodiimide (EDAC), imidazole, N-hydroxsuccinimide (NHS) and dicyclohexylcarbodiimide (DCC), HOBt (1-hydroxybenzotriazole), ρ-nitrophenylchloroformate, carbonyldiimidazole (CDI), and N,N′-disuccinimidylcarbonate (DSC).
10. A polyelectrolyte complex micelle formed from the conjugate for gene transfer of any one of claims 1 to 7 and a cationic polymer or cationic peptide, wherein formation of the micelle is driven by ionic interaction.
11. The polyelectrolyte complex micelle as set forth in claim 10 , wherein cationic peptide is KALA or protamine.
12. The polyelectrolyte complex micelle as set forth in claim 10 , wherein cationic polymer is one or more selected from polyethylenimine, polyamidoamine, polylysine, diethylaminoethyldextran, polydimethylamino-ethyl methylacrylate, and derivates thereof.
13. A method of preparing a polyelectrolyte complex micelle, comprising inducing ionic interaction between the conjugate for gene transfer of any one of claims 1 to 7 and a cationic polymer or cationic peptide.